Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specific gut microbiota alterations and metabolic deficits in Parkinson's disease: a controlled comparison with functional constipation.

Frontiers in cellular and infection microbiology·2026
Same author

Luminescent Properties and Optical Temperature Sensing Performance of CaTa<sub>2</sub>O<sub>6</sub>:Pr<sup>3+</sup> Phosphors Under Blue-Light Excitation.

Materials (Basel, Switzerland)·2026
Same author

The Effects of Different Culture Modes on the Nutritional Quality of <i>Procambarus clarkii</i> and Mechanistic Insights: A Metabolomic Perspective.

Biology·2026
Same author

Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses.

Therapeutic innovation & regulatory science·2026
Same author

Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of <sup>177</sup>Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells.

Cancer biotherapy & radiopharmaceuticals·2026
Same author

Deciphering microenvironmental heterogeneity by scalable Niche Guided Module Discovery.

Communications biology·2026

Related Experiment Video

Updated: Nov 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.3K

B-Lymphoblastic Leukemia With Aberrant CD5 Expression.

Matthew T Ye1, Jia Zhu1,2, David X Luo1

  • 1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

American Journal of Clinical Pathology
|April 6, 2021
PubMed
Summary
This summary is machine-generated.

Aberrant CD5 expression in B-acute lymphoblastic leukemia (B-ALL) is rare and linked to poorer survival outcomes. Recognizing CD5+ B-ALL is crucial for accurate diagnosis and treatment of B-cell lymphoproliferative disorders.

Keywords:
B-acute lymphoblastic leukemiaCD5Short overall survival

More Related Videos

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.5K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.3K

Related Experiment Videos

Last Updated: Nov 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.3K
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.5K
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunophenotyping

Background:

  • B-acute lymphoblastic leukemia (B-ALL) is a cancer of immature B-lymphoid cells.
  • CD5 expression is an unusual finding in B-ALL, typically seen in other B-cell malignancies.

Purpose of the Study:

  • To investigate the characteristics of B-ALL with aberrant CD5 expression.
  • To compare CD5+ B-ALL with CD5- B-ALL cases.
  • To clarify the diagnostic challenges posed by CD5+ B-ALL.

Main Methods:

  • Clinicopathologic, immunophenotypic, and molecular genetic analysis of 10 B-ALL cases with CD5 expression.
  • Comparative analysis with B-ALL cases lacking CD5 expression.

Main Results:

  • CD5+ B-ALL predominantly affects males and is associated with significantly shorter overall survival (21 vs 45 months).
  • CD5 expression complicates differential diagnosis with blastic B-cell lymphomas.
  • Specific immunophenotypic markers (dim CD20/CD45, CD34+, TdT+, sIg-, cyclin D1-, t(11;14)-) aid in diagnosing B-ALL.

Conclusions:

  • CD5 expression in B-ALL is rare and indicates a poor prognosis.
  • CD5+ B-ALL is a distinct entity requiring consideration in the differential diagnosis of CD5+ B-cell lymphoproliferative disorders.